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Preface  
 
I 
Abstract 
 
 
 
Duchenne muscular dystrophy (DMD) is the second most commonly inherited 
disorder in man, the phenotype of which displays pathological characteristics of 
altered skeletal muscle function including, amongst others, abnormal Ca
2+
 
homeostasis and cell signaling.  This study used the mdx mouse model of DMD to 
analyse purinergic responses in dystrophic muscle cells in vitro and skeletal muscles 
in situ. Initial investigations excluded reduction in ATPe hydrolysing potential from 
explaining previous observations of heightened nucleotide sensitivities in dystrophic 
myoblasts. Instead, this study demonstrates for the first time that significant P2X7 
receptor abnormalities exist in dystrophic myoblasts and skeletal muscles of the adult 
mdx mouse; significantly elevated levels of P2X7 receptor mRNA and protein 
expression were found in primary myoblast cultures, myoblast lines and muscles in 
situ at 4 months of age and this was extended to analysis of changes in individual 
P2X7 splice variants.  These abnormalities were shown to extend to functional 
responses in cultured myoblast lines, where heightened P2X7 receptor-specific 
sensitivity was shown to be associated with significantly higher basal and induced 
levels of, and altered time course of, extracellular-signal regulated kinase (ERK1/2) 
phosphorylation in dystrophic myoblasts.  ERK activation responses were shown to 
be inducible by ATP and BzATP stimulation, inhibited by P2X7 antagonists, and 
unresponsive to ivermectin, thus confirming P2X7 receptor involvement.  Similar 
 iii 
 
 
up-regulation of P2X7 receptor expression coinciding with ERK phosphorylation 
was demonstrated in mdx muscles in vivo.  Additionally, NAD was identified as a 
mediator of P2X7 responses in dystrophic myoblasts.  This study has also employed 
a mass spectrometry based approach to investigate the immediate downstream effects 
of P2X7 activation in cultured myoblasts; allowing identification of multiple 
potential signaling relays for future study that are discussed.  The potential for a link 
between P2X7 receptor and dystrophin expression has been suggested here through 
the demonstration that abnormalities in P2X7 receptor expression and function are 
corrected by micro-dystrophin expression in dystrophic myoblasts.   
In vivo pharmacological P2X7 receptor inhibition using CBBG significantly 
reduced the number of revertant fibres in dystrophic muscle, indicating a reduction in 
degenerative/regenerative activity.  The data presented in this thesis highlight a novel 
role for P2X7 receptor signaling in dystrophic myoblasts and muscles in situ; 
proposing the potential for beneficial therapeutic strategies aimed at manipulating 
P2X7 signaling responses in vivo, with a view to slowing the progression of what is 
at present an incurable and invariably fatal disease. 
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